EyePoint Pharmaceuticals Inc (PSDV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH3119D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

December 2018

Total pages

55

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint's iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

EyePoint Pharmaceuticals Inc (PSDV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

EyePoint Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

EyePoint Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

pSivida and Nicox Enter into Agreement 13

pSivida Enters into Agreement with Major Global Pharmaceutical Company 14

Licensing Agreements 15

Ocumension Therapeutics Enters into Licensing Agreement with EyePoint Pharma 15

Equity Offering 16

EyePoint Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 16

EyePoint Pharma Raises USD28.9 Million in Private Placement in Shares upon Exercise of Warrants 17

EyePoint Pharma Plans to Raise Funds through Public Offering of Shares 18

EyePoint Pharma to Raise USD25.5 Million in Private Placement in Second Tranche of Units 19

EyePoint Pharma Raises USD9.5 Million in Private Placement of Securities 20

EyePoint Pharma Raises USD0.5 Million in Private Placement of Securities 21

pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 22

pSivida Raises USD17.8 Million in Public Offering of Shares 23

pSivida Raises USD7 Million in Private Placement of Shares 25

pSivida Announces Private Placement Of Shares For USD 19 Million 26

pSivida Completes Public Offering Of Shares For USD 10.8 Million 27

pSivida Completes Private Placement Of Units For USD 5.4 Million 28

Acquisition 29

pSivida Acquires Icon Bioscience 29

EyePoint Pharmaceuticals Inc-Key Competitors 31

EyePoint Pharmaceuticals Inc-Key Employees 32

EyePoint Pharmaceuticals Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

Nov 06, 2018: EyePoint Pharmaceuticals reports fiscal first quarter 2019 financial results and highlights recent clinical and operational developments 34

Sep 12, 2018: EyePoint Pharmaceuticals reports fiscal 2018 fourth quarter & full year financial results and highlights recent progress 36

May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results 39

Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines 41

Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution 42

Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results 43

May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track 44

May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results 45

May 04, 2017: pSivida Q3 net loss increases 46

Feb 07, 2017: pSivida Reports Fiscal 2017 Second Quarter and First Half Results 47

Corporate Communications 49

Nov 27, 2018: EyePoint Pharmaceuticals names Ron Honig, Esq., as SVP, general counsel & company secretary 49

Oct 30, 2018: EyePoint Pharmaceuticals appoints John Landis, Ph.D., M.S., to Board of Directors 50

Sep 10, 2018: EyePoint Pharmaceuticals names Goran Ando as Next Chairman of Board of Directors 51

Aug 15, 2018: Eyepoint Pharmaceuticals appoints John Weet, Ph.D., as SVP, regulatory affairs & quality 52

Jun 26, 2018: EyePoint Pharmaceuticals Names Goran Ando As Board Director 53

Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List of Figure

List of Figures

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

EyePoint Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List of Table

List of Tables

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

EyePoint Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

EyePoint Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

EyePoint Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

pSivida and Nicox Enter into Agreement 13

pSivida Enters into Agreement with Major Global Pharmaceutical Company 14

Ocumension Therapeutics Enters into Licensing Agreement with EyePoint Pharma 15

EyePoint Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 16

EyePoint Pharma Raises USD28.9 Million in Private Placement in Shares upon Exercise of Warrants 17

EyePoint Pharma Plans to Raise Funds through Public Offering of Shares 18

EyePoint Pharma to Raise USD25.5 Million in Private Placement in Second Tranche of Units 19

EyePoint Pharma Raises USD9.5 Million in Private Placement of Securities 20

EyePoint Pharma Raises USD0.5 Million in Private Placement of Securities 21

pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 22

pSivida Raises USD17.8 Million in Public Offering of Shares 23

pSivida Raises USD7 Million in Private Placement of Shares 25

pSivida Announces Private Placement Of Shares For USD 19 Million 26

pSivida Completes Public Offering Of Shares For USD 10.8 Million 27

pSivida Completes Private Placement Of Units For USD 5.4 Million 28

pSivida Acquires Icon Bioscience 29

EyePoint Pharmaceuticals Inc, Key Competitors 31

EyePoint Pharmaceuticals Inc, Key Employees 32

EyePoint Pharmaceuticals Inc, Subsidiaries 33

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022